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 ABSTRACT 
G-protein-coupled receptors (GPCRs), which are the largest class of cell-surface 
receptors, are involved in a range of physiologic processes and pathologies, mak-
ing this a highly interesting group of proteins as targets for drug development. 
Studies of these receptors have uncovered novel receptor biology concepts, in-
cluding biased signaling, functional selectivity, and allosteric modulation. “Tai-
lor-made” lipopeptides (pepducins and lipopeptoids) represent novel and 
promising classes of receptor-specific allosteric modulators. In this thesis, im-
munomodulating lipopeptides that interact with a group of pattern recognition 
receptors, formyl peptide receptors (FPRs), which play key roles in host defense 
against microbial infections, tissue homeostasis, and the initiation and resolution 
of inflammation, are generated and functionally characterized. The FPRs are ex-
pressed in both human and murine white blood cells, and novel allosteric 
lipopeptide modulators that selectively interact with human and murine recep-
tors are described. We show that the targeted receptor is not always the one that 
might be expected. This receptor hijacking process raises questions about the 
precise mechanisms of action of these lipopeptides and of these types of mole-
cules acting as a molecular pattern that is recognized by the receptor group stud-
ied. Fundamental differences are also revealed by the receptor-ligand recognition 
profiles, between mice and men. This represents important knowledge needed 
for the development and use of animal models for human diseases. 
In summary, the results presented in this thesis not only highlight the value of 
the different lipopeptides as tools for modulating receptor activities in human 
and murine immune cells, but also provide new insights into the allosteric mod-
ulation concept.  
 
Keywords: Human, mouse, neutrophil, reactive oxygen species, formyl peptide 
receptor, pepducin, G-protein-coupled receptor, lipopeptoid, pattern recogni-
tion receptor 
  
POPULÄRVETENSKAPLIG 
SAMMANFATTNING 
Receptorer som för sin signalering är beroende av ett s.k. G-protein utgör den 
största gruppen av igenkänningsstukturer som uttryck på våra cellers yta. Dessa 
receptorer är av stor betydelse för styrningen av många fysiologiska processer 
och ett fel i signalsystemet (för stark eller för svag signal, eller signalering vid fel 
tillfälle) riskerar att leda till sjukdom. Detta gör att kunskaper om denna grupp 
av receptorer har kunnat (och kommer att kunna) användas för att utveckla lä-
kemedel mot många typer av sjukdomar, och forskningen inom området är både 
omfattande och expanderande. När den här gruppen av receptor beskrevs var 
uppfattningen att det fanns två aktivitetslägen, antingen på eller av, men senare 
forskning visar att styrsystemen är mycket mer komplexa och begrepp som 
funktionell selektivitet, ”biased” signalering, full/partiell/invers agonism, och al-
losterisk modulering, används idag för att beskriva komplexiteten. Den grupp av 
lipopeptider som kallas pepduciner och som flera av delarbetena i denna avhand-
ling beskriver, är en grupp av modulatorer. Normalt aktiveras en receptor genom 
att en informationsbärare binder till delar av receptorn som är tillgängliga från 
cellens utsida, och denna bindning ändrar receptors funktion så att information 
förs vidare till det signalerande G-proteinet på insidan av cellens membran. 
Pepduciner, som består av en kort kedja av aminosyror (peptid) ihopkopplade 
med en så kalla fettsyra, har förmåga att ta sig in i celler och binda till delar av 
receptorer som är tillgängliga från insidan och de kan antingen aktivera samma 
signaler som en informationsbärare som kommer utifrån (positiv allosterisk mo-
dulering), eller hindra signalen att gå fram trots att informationsbäraren bundit 
till receptorn (negativ allosterisk modulering). En pepducin påverkar inte funkt-
ionen av vilken receptor som helst, utan bara de receptorer som någonstans på 
insidan av cellens membran själv har en peptidkedja som innehåller samma ami-
nosyror som pepducinen och de skall dessutom finnas i samma inbördes ord-
ning. Detta avhandlingsarbete visar att det inte alltid fungerar så; flera pepduciner 
och andra lipopeptider känner igen en speciell receptor (formyl peptide receptor 
2; FPR2) trots att den kedja av aminosyror som förmodats vara avgörande för 
funktion, saknas i denna receptor.  
 I arbete I i avhandlingen undersöks effekter av pepduciner med en palmitinsyra 
(fettsyra) kopplad till en kedja aminosyror som är identisk eller nästan identisk 
med en bit (den tredje intracellulära loopen) som finns på en av de delar av re-
ceptorn FPR2 som exponeras på insidan av vita blodkroppars membran. I detta 
arbete (och i ett av forskargruppen tidigare publicerat arbete) visas att det finns 
en klar koppling mellan pepducinens aminosyrasekvens och den som finns i den 
receptor som aktiveras, men dessutom kan dessa pepduciner döda bakterier. 
Även denna funktion var helt beroende av att både fettsyra och peptidkedja, men 
basen för de två olika funktionerna (aktivering av vita blodkroppar - avdödning 
av bakterier) skiljer sig åt. De resultat som presenteras väcker frågan om det 
skulle vara möjligt att i framtiden kombinera de bakteriedödande och de immu-
nomodulerande egenskaperna i en klass av nya antibakteriella läkemedel. 
I arbete II i avhandlingen undersöks effekter av en pepducin med samma fettsyra 
som i de tidigare undersökta pepducinerna men med en kedja aminosyror som 
hämtats från en annan receptor, den med FPR2 närbesläktade FPR1. Aminosy-
rasekvensen är identisk med det tredje intracellulära loop i FPR1. I motsats till 
den tidigare beskrivna pepducinen som aktiverade vita blodkroppar, så hämmade 
FPR1-pepducinen cellernas funktion, men det var inte FPR1 funktionen som 
hämmades, utan den här pepducinen "kidnappade" FPR2. Dessa resultat väcker 
frågor om själva pepducinkonceptet och dessa frågor får ytterligare näring av att 
den här pepducinen påverkar extracellulära signalmolekylers förmåga att binda 
till receptorn på cellernas utsida.  
I arbete III studeras vita blodkroppar från försöksdjur, allt i avsikt att undersöka 
funktionslikheter/skillnader mellan mus och människa som båda är utrustade 
med de receptorer som beskrivits i arbete I och II, FPR1 (som i mus fått heta 
Fpr1) och FPR2 (som i mus fått heta Fpr2). Ett relativt stort antal agonister (ak-
tiverare) och antagonister (hämmare) har beskrivits och dessa påverkar selektivt 
FPR1 respektive FPR2, eller båda receptorerna. Mycket hur fungerar dessa re-
ceptor ligander i relation till motsvarande musreceptorer? Genom att använda 
vita blodkroppar som isolerats från benmärg tagen från normal friska möss och 
från djur som saknar arvsanlaget för Fpr2, identifierades ett par specifika agonis-
ter för Fpr1 respektive Fpr2, och tillgången till en dess specifika agonister gjorde 
det möjligt att identifiera receptorspecifika antagonister för dessa musrecepto-
rerna. De absolut bästa FPR1 och FPR2 antagonisterna hade inga hämmande 
effekter på motsvarande musreceptorer, men en mindre potent FPR1 antagonist 
visas fungera också för att hämma funktionen av Fpr1. En ny potent och selektiv 
Fpr2 hämmare (Lau-(Lys-βNSpe)6-NH2 introduceras. Denna hämmare tillhör en 
grupp av molekyler som brukar kallas lipopeptoider, och har en fettsyra kopplat 
till en kedja som är uppbyggd av kemiskt modifierade, "onormala", aminosyror.  
I arbetet IV studerades effekter på Fpr1/Fpr2 (musreceptorerna) av pepduciner 
med peptiddelarna hämtade från motsvarande humana receptorer, och det om-
vända. De två "humana pepducinerna" (beskrivna i arbetena I och II) är struk-
turellt väldigt lika (olika aminosyror på två ställen i peptiderna) men skiljer i 
funktion; den ena hämmar och den andra aktiverar, men båda är selektiva för 
FPR2. Båda dessa pepduciner modulerar också selektivt Fpr2 men båda aktiverar 
musreceptorn. Mus Fpr1 pepducinen har en peptidkedja som är mycket lik mot-
svarande humana variant (skiljer i en aminosyra) och de har också samma effek-
ter; aktiverar funktionen av Fpr2 och hämmar den av FPR2. Den pepducin som 
är hämtad från Fpr2 hämmar funktionen av denna receptor med den hämmar 
också funktionen av FPR2 trots att det är ganska stora skillnader mellan dessa 
receptorer i delar av respektive receptor som finns på insidan av de vita blod-
kropparnas membran. Sammanfattningsvis fungerar pepduciner som bra verktyg 
som kan användas för att modulera receptorfunktion, men det är uppenbart att 
det inte bara finns en mekanism för hur de fungerar.  
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INTRODUCTION TO  
RECEPTOR BIOLOGY 
All living cells must be able to sense the environment and respond to changes that 
affect survival, reproduction, and cell-to-cell communication. Proteins whose main 
function is to sense and transmit signals that lead to regulation of cellular responses 
to chemical/physical changes in the environment are referred to as receptors (the 
unit that receives a signal/message). Such proteins are carried by all living cells and 
are expressed either inside the cell or on the cell surface. Cells have an elaborate 
repertoire of receptors, with collective specificities for a multitude of stimuli, includ-
ing nutrients, growth factors, hormones, and toxins. Stimulation of these receptors 
activates signal transduction mechanisms, which produce chemical signals to mediate 
a wide range of cellular responses. These responses regulate many different cellular 
activities, such as cytoskeletal alterations, metabolism, and gene expression. Intracel-
lular receptors are located in the cytoplasm, nucleus or vacuoles of the cell and are 
activated by signaling molecules that are generated intracellularly or molecules that 
can pass through cell membranes. 
While receptors that are expressed on the surface of a cell can be connected to the 
membrane in different ways (e.g., membrane associated/anchored or integral to the 
membrane), they have in common that they all recognize external signals and transfer 
the information about the presence/absence of a particular signal to an intracellular 
signal, which is transferred to second messengers and ultimately, to effector functions 
related to the receptor involved and the precise signal received. The cell-surface re-
ceptors that are involved in the signaling processes that occur in multicellular organ-
isms can be divided into three general categories: receptors with ion channel activities; 
receptors with enzymatic activities; and receptors that rely on a G-protein for signal 
transduction, the so-called G-protein-coupled receptors (GPCRs). The last category 
is the largest receptor family, encoding approximately 950 GPCR members in the 
human genome, and will be the focus of this thesis.   
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G-PROTEIN-COUPLED 
RECEPTORS  
Knowledge about the family of receptors now known as GPCRs was initially ob-
tained from studies of the light-sensitive receptor rhodopsin, which was the first 
GPCR to be studied in detail. The possibility to obtain large quantities of a highly 
enriched and stable protein from the bovine retina supported these studies, which 
resulted in the publication of the primary sequence of rhodopsin in 1983 [1]. Around 
10 years later, the two-dimensional crystal structure of bovine rhodopsin was ob-
tained, and the three-dimensional crystal structure was obtained in Year 2000 [2, 3]. 
GPCRs have in common that they are membrane-spanning proteins that traverse 
seven times the membrane in which they are expressed, placing the N- and C-termini 
on different sides of the membrane [1, 4]. The importance for signaling of 
GTP/GDP-binding heterotrimeric proteins (large G-proteins) was known before 
this group of proteins was proposed to act as intermediate transducers of the second 
messenger signals generated by GPCRs [5, 6]. The β-adrenergic receptor was the first 
receptor in the family to be cloned, and the basic functions of this receptor has since 
then been used as the prototypic GPCR [7]. We now know that even if the family 
members in the GPCR superfamily share common structural features, e.g., seven α-
helical transmembrane domains and alternating cytoplasmic and extracellular loops, 
there is significant diversity among these receptors. GPCRs regulate a vast number 
of basic biological functions, as well as physiological processes, ranging from vision 
and smell to neurologic, cardiovascular, and reproductive functions. GPCRs cur-
rently constitute major targets for drug development and indeed, more than 40% of 
drugs that are currently on the market target GPCRs [8-10]. The importance of 
GPCRs is evidenced by the Nobel Prizes awarded to researchers describing the role 
of G-proteins in signal transduction (Gilman and Rodbell, 1994), the biological ac-
tivities of GPCR-binding neurotransmitters (Kandel, Carlsson and, Greenard, 2000), 
the description of olfactory GPCRs (Axel and Buck, 2004), and the GPCR structure-
function relationships (Lefkowitz and Kobilka, 2012).  
Several classification systems have been used to categorize this superfamily of recep-
tors. The first and most frequently used classification system is based on sequence 
G-PROTEIN-COUPLED 
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homology, dividing the GPCRs into the following six classes: A, rhodopsin-like; B, 
secretin receptor family); C, metabotropic glutamate; D, fungal mating pheromone 
receptors: E. cyclic AMP receptors; and F, frizzled. Of these, none of the receptors 
that belong to the D and E classes has been found in vertebrates. An alternative 
classification system is the GRAFS system introduced by Fredriksson et al in 2003, 
which is based on the GPCR phylogenetic tree. This system divides vertebrate 
GPCRs into five subgroups, overlapping the A–F nomenclature: glutamate; rhodop-
sin; adhesion; frizzled/taste; and secretin (Figure 1) [11-14]. The GPCRs are known 
to recognize and respond to many different types of ligand, from photons, neuro-
transmitters, and hormones to inflammatory mediators belonging to different chem-
ical groups [15, 16]. Despite the diverse range of GPCR ligands, many receptors  
Figure 1. Phylogenetic tree of the human GPCR superfamily constructed using sequence similarities within 
the seven-transmembrane regions. The GPCRs are listed according to the gene name used in the UniProt 
database. Family members with known structure are indicated by the blue circles within the tree. The 
turquoise circle highlights the three FPR family members (FPR1, FPR2, FPR3). Adapted from [17]. 
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share structural similarities (e.g., seven transmembrane domains) and use simi-
lar/identical G-protein-dependent intracellular signaling pathways to regulate differ-
ent cell functions [14, 16]. 
Basic concepts underlying orthosteric ligand  
regulation of GPCR activity 
In the classic two-state model that describes the interaction between a ligand and its 
receptor, the conformation of a receptor can vary between two different states that 
are in equilibrium [18]. In one conformational state, the signaling is turned off, 
whereas in the other state the signaling is on. Depending on the direction of the 
equilibrium (towards ‘on’ or ‘off’), the basic activities of receptors may vary. Ligand 
binding will then change the conformation of the receptor and thereby alter its acti-
vation state. GPCR ligands that bind to sites for natural ligands, so called orthosteric 
sites that are situated on parts of the receptor that are exposed on the extracellular 
side of the membrane, are accordingly termed orthosteric ligands. Based on the phys-
iologic effect that is induced, this type of ligand stabilizes the receptor in a confor-
mational state whereby the signaling is switched off (inverse agonist), partially on (a  
Figure 2. Hypothetical dose-response curves induced by different types of receptor-targeting ligands. A 
full agonist elicits the maximal response following receptor occupation and activation, whereas a partial 
agonist is unable to elicit the maximal response through the same receptor and inverse agonist binds to the 
same receptor-binding site as the agonist but reverses the constitutive activity of the receptor, thereby 
exerting pharmacologic effects opposite to those of the agonist. A neutral antagonist is a drug that binds to 
the same site as the agonist and blocks the effect of an agonist. Adapted from https://en.wikipe-
dia.org/wiki/Inverse_agonist#/media/File:Inverse_agonist_3.svg under the Creative Commons licence CC 
BY-SA 4.0. 
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partial agonist), fully on (full agonist) or has no effect on the conformation but blocks 
the binding of other ligands (antagonist) (Figure 2) [19-22]. 
It is clear from more recent work conducted on GPCRs, that the classical two-state 
model for how signaling is turned on and off is inadequate for describing the dynamic 
systems that regulate receptor function. This is clearly illustrated by the effects ob-
served for allosteric and biased ligands. The ternary complex model for GPCR acti-
vation, which describes a receptor that moves laterally in the cell membrane to couple 
physically with a trimeric G-protein after activation by an agonist, only accounts for 
part of the complexity of GPCR signaling system. Recent theories have revised the 
ternary complex model to reflect that a receptor may exist in many active confor-
mation states [23, 24]. A criticism of this revisionism is that not all of these potential 
conformations may be physiologically relevant. 
Allosteric modulators of GPCR 
GPCRs are protein structures that transmit chemical signals across the cell mem-
brane. Accordingly, agonist binding to the extracellular domains of a receptor induces 
a conformational change in those parts of the receptor that are located on the cyto-
solic side of the membrane, which leads to activation of the G-protein. In addition 
to endogenous (natural) ligand binding to the orthosteric binding site, GPCRs may 
expose allosteric (Greek for “other site”) binding sites that are topographically dis-
tinct from the orthosteric site [25]. Ligands that interact with an allosteric binding site 
are called allosteric modulators, and while they may functionally resemble agonists, 
antagonists or inverse agonists, they may also modulate basic functions induced by 
ligands that interact with the orthosteric binding site of the receptor [20, 26]. De-
pending on its effects on an orthosteric agonist (increasing or decreasing activity), an 
allosteric modulator can be classified as a positive allosteric modulator (PAM) or a 
negative allosteric modulator (NAM) [27-30]. Allosteric ligands modulate the recep-
tor in two ways: 1) affinity modulation with conformational change to the receptor; 
and 2) modulation of efficacy by changing the intracellular signaling capacity (Figure 
3).  
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Figure 3. Signaling directed by a G-protein and/or β-arrestin. A conventional/orthosteric/natural GPCR 
agonist triggers activation of the G-protein- and β-arrestin-mediated signaling pathways (left panel). A biased 
GPCR agonist triggers selectively or primarily activation of the G-protein-mediated signaling pathway (mid-
dle panel) or the β-arrestin-mediated signaling pathway (right panel). 
 
In GPCR-based drug discovery, the recent identification of allosteric modulators for 
certain GPCRs represents a major breakthrough. Traditionally, GPCR-based drug 
screening programs have identified drug candidates that target the orthosteric bind-
ing sites, making it difficult to achieve high selectivity for specific GPCR subtypes, 
given that these sites are often highly conserved across members of the single GPCR 
subfamily. Furthermore, ligands that bind at orthosteric sites for some GPCRs, such 
as peptide or protein receptors, have other physicochemical and pharmacokinetic 
properties that are incompatible with scaffolds, which are useful for small molecule 
drug discovery. Thus, the development of selective allosteric modulators for a spe-
cific receptor serves as an alternative approach. In vivo, these agents can also have the 
specific advantage of modulating exclusively receptor activity when the orthosteric 
agonist is present to occupy the receptor, thereby maintaining spatial and temporal 
control of receptor signaling [20, 30-32]. A classic example of a PAM is the benzodi-
azepines used for modulating GABA receptors, providing an effective and safe ap-
proach to the treatment of anxiety and sleep disorders [33]. 
G-protein-dependent signalling  
downstream GPCRs 
GPCRs generally signal through coupling to heterotrimeric guanine nucleotide-bind-
ing proteins (G-proteins) that are composed of an α-subunit and a heteromeric βγ-
complex. However, there are exceptions to this (see discussion of biased signaling 
below). There are four main α-subunits (Gα S, Gα 12, Gα q and Gα i/0) and they can be 
combined with at least 5 different β-subunits and 12 different γ-subunits. The activity 
G-PROTEIN-COUPLED 
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of a G-protein is regulated by GDP/GTP exchange in the α-subunit, which is inac-
tive in its GDP-bound form and active when it is separated from the βγ-complex in 
the GTP-bound form. Upon ligand binding, the conformational change of the ago-
nist-occupied receptor initiates the GDP/GTP exchange, which results in dissocia-
tion of the βγ-complex from the α-subunit [34-36]. It is now well established that not 
only the α-subunit, but also the βγ -complex is active in signaling. Activation of phos-
pholipase C (PLC) is an early signal initiated by the activated α and βγ complexes that 
secondarily generates further downstream messengers produced during hydrolysis of 
the lipid phosphatidyl inositol bisphosphate (PIP2), giving rise to diacylglycerol 
(DAG) and Inositol 1,4,5-triphosphate (IP3). IP3 triggers the release of Ca2+ from 
intracellular storage organelles and DAG activates protein kinase C (PKC), which is 
a kinase that is associated, for example, with activation of the superoxide-generating 
NADPH-oxidase in neutrophils. The phosphoinositide 3-kinase (PI3K) is activated 
together with other kinases, such as the extracellular signal-regulating kinase 
(ERK1/2), p38 MAP kinase, and the guanine-nucleotide exchange factors (GEFs). 
GEFs regulate small G-proteins of the Rho family (Rho, Rac, Cdc42), which are key 
regulators of several cellular functions [37-40] (for more information see review [41]).  
Figure 4. Schematic of the main G-protein-mediated signaling pathways downstream of FPR. Agonist bind-
ing to FPR results in dissociation of the heterotrimeric G-protein complex into Gα-GTP and the Gβγ-
subunits, leading to activation of downstream signaling cascades and effector functions, including ROS pro-
duction, degranulation, and transcriptional responses 
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Biased signalling and β-arrestin binding  
downstream of activated GPCRs 
The classic two-state model for receptor activation was challenged when the concept 
of biased signaling was introduced around 10 years ago [42-44]. Recent research has 
demonstrated that the binding of different agonists to the same receptor induces 
conformational changes in the cytoplasmic signaling domains of the occupied recep-
tor, which triggers signals cascades with or without the direct involvement of a G-
protein (Figure 3) [45]. The recruitment and binding of β-arrestins to an activated 
GPCR blocks G-protein binding; this was initially described as the mechanism for 
the termination of signaling, but we now know that β-arrestin is an endocytic adaptor 
protein with its own signaling properties that are independent of any G-protein [46, 
47]. To date, only a few receptors have been shown to possess this β-arrestin-medi-
ated biased signaling characteristic, and the precise mechanisms and biological con-
sequences of biased signaling have not yet been clarified, even though this is currently 
one of the most intensively studied topics in the field of GPCR signaling [48-51].  
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PEPDUCINS – A NOVEL CONCEPT 
FOR THE REGULATION OF  
GPCR FUNCTION  
The findings that GPCRs constitute a large protein family of interest for drug devel-
opment (approximately 40% of drugs currently on the market are GPCR-based) and 
that allosteric modulators are promising drug candidates inspired Covic and col-
leagues to introduce a novel concept for GPCR modulation. They showed that a 
group of membrane-penetrating lipopeptides, named pepducins, could be used to 
modulate allosterically GPCR signaling [17, 52]. The N-terminal lipid part (usually 
palmitate) of a pepducin makes the molecule membrane-permeable, while the peptide 
portion, with sequence identical to that of one of the intracellular loops or the tail of 
a GPCR, determines receptor preference and selectivity. It has been suggested that 
the lipid group anchors the pepducin to the membrane, a process that is rapidly and 
efficiently followed by flipping of the peptide part, such that the peptide sequence 
becomes exposed on the inner side of the plasma membrane. A direct modulatory 
effect is then achieved through allosteric modulation of receptor signaling, with the  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Proposed mechanism for pepducin activities. A 
pepducin is a fatty acid-conjugated peptide with a peptide se-
quence identical to one of the intracellular domains of a 
GPCR (see 1). The fatty acid anchors the pepducin to the cell 
membrane and the peptide part flips and translocates across 
the membrane (see 2-3). Once inside the membrane, the pep-
tide part of the pepducin interferes with the signaling domains 
of the receptor and either activates or inhibits receptor func-
tion (see 4). 
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outcome of either inhibition or direct activation of the cognate GPCRs from which 
the peptide sequence is derived (Figure 5) [17, 52-54].  
The conceptual difference between pepducins and orthosteric ligands is that the 
functions of the targeted receptor are regulated from the outside of the cell by or-
thosteric ligands and from the inside of the cell by pepducins. For orthosteric ligands, 
receptor selectivity is achieved through precise fitting of the ligand to a defined and 
unique three-dimensional binding pocket that is available in the targeted receptor, 
whereas the pepducin relies on amino acid sequence identity between the pepducin 
and the targeted receptor. Several criteria must be fulfilled for the pepducin concept 
to be valid. One of these criteria is that there should be a difference in activity be-
tween the fatty acid-linked peptide and the non-lipidated peptide. In this respect, it is 
clear that in order for pepducins to be active, the presence of the hydrophobic fatty 
acid is essential (this applies to all pepducins described), and the fatty acid possibly 
facilitates plasma membrane passage [53, 55-58]. However, this does not conclusively 
prove that pepducins initiate signaling through interactions with domains that are 
facing the cytosol, and it is a much more challenging task to prove rather than merely 
show that the peptide can pass through the membrane. Another criterion is that the 
pepducin should be able to trigger a response in cells that express the targeted recep-
tor only. However, this is also the case for orthosteric extracellular receptor agonists 
and it is by no means a unique property of pepducins. Moreover, according to the 
pepducin concept, the functional activities of pepducins should not be affected by 
conventional antagonists, and their binding should not be affected by conventional 
receptor agonists or antagonists. 
Activating and inhibiting pepducins  
The pepducin concept has prompted the design of different palmitoylated peptide 
sequences derived from a number of GPCRs, among which the pepducins derived 
from the protease-activated receptor (PAR1) are the most studied. A 19-amino acid 
pepducin (P1pal-19) derived from the third intracellular loop of PAR1 selectively 
induced a Ca2+ response in PAR1-expressing cells, and the response was identical to 
that induced by a conventional PAR1 agonist [52]. More importantly, that previous 
study shows that a PAR1 antagonist that inhibits the conventional PAR1 agonist has 
no effect on the P1pal-19-induced Ca2+ response and that a mutant PAR1 receptor 
with deletion of the entire C-terminal tail responds to a conventional agonist but does 
not respond to the pepducin. This suggested that the C-tail of PAR1 was required 
for pepducin binding, and the data obtained represented a proof of principle for re-
ceptor-modulating pepducins [52]. Pepducins with amino acid sequences identical to 
other intracellular domains of PAR1 or those of other members of the PAR family 
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(PAR1, PAR2, and PAR4) have been identified and shown to exert either receptor-
activating or receptor-inhibiting functions [53, 57, 59-61]. The precise mechanism of 
action has been studied using a PAR1 pepducin and a FRET-based assay to deter-
mine binding, and the results indicate that the pepducin is located close to the inner 
leaflet of the plasma membrane [58].  
A library screen using pepducins derived from the intracellular domains of chemo-
kine receptor type 4 (CXCR4) identified several activating pepducins with amino acid 
sequences identical to those in the first intracellular loop of the receptor. One of 
these pepducins, ATI2341, has been shown to induce a CXCR4-dependent Ca2+ in-
crease, chemotactic migration, and mobilization of white blood cells from the bone 
marrow [62]. A bioluminescence resonance energy transfer (BRET) assay system has 
been used to determine pepducin-induced recruitment to CXCR4 of different G-
proteins (Gαi, Gα13) and β-arrestin, respectively, and it has been shown that this 
CXCR4 pepducin is a biased CXCR4 agonist, promoting the engagement and activa-
tion of Gαi but not of Gα13 or β-arrestin [56]. In addition, a pepducin derived from 
the second intracellular loop of the sphingosine-1-phosphate receptor (S1P3 or 
EGD3) has been shown to induce cellular responses similar to those induced by the 
conventional agonist [63].  
Receptor-specific pepducins have also been identified for the adrenergic receptor and 
the formyl peptide receptor 2 (FPR2) [64, 65]. Pharmacokinetic, pharmacodynamic, 
and bio-distribution studies have shown that pepducins are widely distributed 
throughout the body, with the exception of the brain, and possess drug-like proper-
ties that make them appropriate for use in vivo [66]. The beneficial effects of 
pepducins have been observed in several mice disease models [58, 59, 67-69]. Overall, 
the pepducin concept has been shown to be valid as a means to activate or inhibit 
functional responses mediated by a wide range of receptors (Table 1), which suggests 
that this type of allosterically modulating lipopeptide may be a valuable tool for basic 
GPCR research and for de-orphanizing receptors for which no agonists have yet been 
identified. 
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Table 1. List of selected pepducins.1 
Ligand Loop2 Derived3 Effect Reference 
P1pal12 i3 PAR1 Antagonist [52, 53, 67, 70] 
P1pal19 i3 PAR1 Agonist [52, 61] 
P2pal8S i3 PAR2 Antagonist [71] 
P4pal10 i3 PAR4 Antagonist [72, 73] 
P4pal-i1 i1 PAR4 Antagonist [60, 74] 
F2pal10 i3 FPR2 Agonist [75] 
x1/2pal-i3 i3 CXCR1/CXCR2 Antagonist [59] [76] 
x4pal-i1 i1 CXCR4 Antagonist [59] 
ATI-2341 i3 CXCR4 Agonist [59] [62] 
KRX-725 i2 S1P3 Agonist [63] 
SMOi2-1 i2 SMO Antagonist [77] 
1Adapted from [59].  
2The intracellular (i) loops are numbered from the N-terminal domain 
3The receptor from which the sequence is derived 
Receptor-independent effects mediated by pepducins   
Pepducins were introduced as a novel type of GPCR modulator with high selectivity 
for their receptors. However, receptor-independent effects have also been observed 
for pepducins. Using a screening approach to search for β2AR pepducins, Carr et al 
[64, 78] identified a number of receptor-dependent pepducins, as well as pepducins 
that activated the cells independent of the receptor, and the mechanism was shown 
to involve direct activation of the downstream Gs-protein. When the effects of this 
Gs-activating pepducin were subsequently studied in neutrophils, the earlier-de-
scribed functional effects induced by Gs-activation were not induced by these 
pepducins in neutrophils, suggesting differences related to the cell type in which the 
Gs-protein is expressed [64, 78]. Another receptor-independent effect of pepducins 
is a direct bactericidal activity (Paper I). Based on similarities in the physico-chemical 
properties between pepducins and a group of naturally occurring antibiotic lipopep-
tides, we hypothesized that pepducins also kill bacteria. We found that pepducins 
exert direct killing of both Gram-positive and Gram-negative bacteria, as well as clin-
ical isolates of pathogenic bacterial species (Paper I). In an era increasing microbial 
resistance to classical antibiotics, there is a need for new antimicrobial drugs. Since 
the first approval of a lipopeptide as an antimicrobial drug back in 2003, this group 
of molecules has received much attention and represents one of the fastest growing 
areas of research in antimicrobial drug discovery [79-81].  
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INNATE IMMUNITY AND THE  
ROLE OF NEUTROPHILS  
While our immune system is vitally important in protection against invading micro-
organisms, it also contributes to tissue injury and disease, as well as to the resolution 
of inflammation and damage repair. The inflammatory reaction is a process that is 
designed to kill, clean, heal, and repair. The immediate local reaction is swelling, red-
ness, pain, heat, and possibly dysfunction of the inflamed tissues. These local reac-
tions depend on an increased blood flow, relaxation effects on blood vessels, the 
release of pro-inflammatory mediators, the extravasation of fluids from the circula-
tion into the infected/inflamed tissue, and the influx of pro-inflammatory cells, which 
are predominantly neutrophil granulocytes, the primary cells in the first line of host 
defense [82]. Dysregulation of the inflammatory response may lead to chronic in-
flammation, as well as auto-inflammatory disorders. Innate immune reactivity is very 
rapid and is constituted by three fundamental steps: i) the recognition of ‘danger’ 
molecules from pathogens or damaged tissue cells; ii) the ability to kill microbial 
pathogens and clean up cell debris; and iii) the ability to minimize host tissue-destruc-
tive activities thereby maintaining self-tolerance.  
The innate immune apparatus is composed of cellular and humoral components, and 
these two parts are linked to recognition and/or effector functions that interact 
within a complex network. The humoral parts consist of many different soluble mol-
ecules that are present in extracellular compartments, including liver-produced acute-
phase proteins, such as LBP (the lipopolysaccharide-binding protein), SAA (serum 
amyloid A), the C-reactive protein, and complement components [83, 84]. The major 
cellular apparatus in inflammatory reactions is the professional phagocyte of myeloid 
origin. Phagocytes differentiate and mature in the bone marrow, and when recruited 
to the bloodstream their commission is to seek and sense invading microbes in the 
tissue and thereafter engulf (phagocytose) and kill these invaders. The neutrophil 
granulocyte is one of the specialized killer cells, the so-called ‘professional phago-
cytes’, being endowed with a broad array of weapons and being of prime importance 
in innate immunity and inflammation [85-87]. 
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The neutrophil granulocyte  
Neutrophils are produced in the bone marrow; in a human adult, 1–2×1011 neutro-
phils are produced every day [88]. The neutrophil differentiation/maturation process 
takes approximately 14 days [89]. Mature neutrophils recruited from the bone mar-
row to the bloodstream will circulate in a naive/resting state, waiting to be recruited 
in response to danger signals emanating from a microbial infection or tissue injury. 
In humans, neutrophils are the most common white blood cell type, and they account 
for 50%–70% of all leukocytes in the peripheral blood. Together with eosinophils 
and basophils, they comprise the subgroup of polymorphonuclear leukocytes (PMN; 
named after the appearance of their multi-lobulated nuclei). These cells are also 
known as granulocytes, a name that reflects the high number of granules in their 
cytoplasm. In neutrophils, these granules (small membrane-enclosed organelles) act 
as storage organelles, containing numerous antimicrobial compounds, proteolytic en-
zymes, and membrane-localized receptors. Neutrophils have at least four different 
types of granules/vesicles, described in more detail below [90-93].  
Two pools of neutrophils are found in peripheral human blood. One is the circulating 
pool (around 50% of the cells), and the other pool comprises neutrophils that are 
loosely attached to the vascular endothelium (known as the ‘marginating pool´) [94]. 
In response to a local infection/inflammation, blood neutrophils are recruited to and 
accumulate at the affected site [94]. This recruitment is a dynamic process that in-
volves several neutrophil functions, all of which are of vital importance for a success-
fully operating immune system. Using an aseptic inflammation skin chamber model, 
in vivo studies have revealed that during the recruitment process substantial amounts 
of various inflammatory mediators and neutrophil granule constituents are pro-
duced/released [95]. These factors are involved in the killing of microbes and in the 
resolution of the inflammatory reaction. The recruited neutrophils are also function-
ally adapted to the conditions at the inflammatory site. Compared to peripheral blood 
neutrophils, the tissue-recruited neutrophils produce higher levels of superoxide 
upon stimulation with certain chemoattractants that are generated by the electron-
transporting NADPH-oxidase within these cells [96]. Functional analysis, as well as 
analysis of cell surface-exposed granule markers reveal that the granule mobilization 
that occurs during tissue recruitment of neutrophils is accompanied by the exposure 
of new receptors for specific chemoattractants, with these receptors being potentially 
mobilized from storage pools through the fusion of granule membranes with the 
plasma membrane [95-102]. Other chemoattractant receptors are downregulated/de-
sensitized, possibly through a hierarchal receptor cross-talk mechanism that is of im-
portance for the recruitment process. In order to be able to exit rapidly from the 
bloodstream and transmigrate through the endothelium and the extravascular tissue, 
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neutrophils are equipped with receptors that recognize PAMPs (pathogen-associated 
molecular patterns, from microbes) or DAMPs (danger-associated molecular pat-
terns, from damaged tissues). Many PAMPs and DAMPs recognize receptors that 
belong to the GPCR superfamily [88, 103]. 
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FUNCTIONS OF NEUTROPHILS 
EXPRESSING GPCRS  
Neutrophils express a number of G-protein-coupled chemoattractant receptors, in-
cluding those that recognize the platelet-activating factor (PAFR), leukotriene B4 
(BLT1/2), and complement fragment 5a (C5aR) [104]. Of the 18 human chemokine 
GPCRs that have been identified, neutrophils are known to express CXCR4, CXCR1, 
and CXCR2 [105]. Most neutrophil GPCRs are coupled to pertussis toxin-sensitive 
G-proteins of the Gαi subgroup, and activation of the chemoattractant/chemokine 
receptors in neutrophils induces not only cellular directional migration, but also the 
release of reactive oxygen species (ROS) generated by the phagocyte NADPH-
oxidase [106]. This oxidase is a multicomponent enzyme made up of a membrane-
bound heterodimeric b-type cytochrome (p22phox and gp91phox/Nox2), the soluble 
cytosolic components of p40phox, p47phox, and p67phox, and the small GTPase Rac. 
Upon chemoattractant stimulation, the soluble components translocate to the b cy-
tochrome, thereby forming an active enzyme that transfers electrons from NADPH 
in the cytosol across the membrane to reduce the oxygen to superoxide anions (O2-) 
(Figure 6) [107-110]. 
In addition to their abilities to activate the NADPH-oxidase, GPCR agonists may 
trigger a secretion process that leads to the mobilization of receptors and adhesion 
molecules from the intracellular storage granules in neutrophils. As mentioned above, 
neutrophils contain at least four different types of granules/vesicles, which are 
formed at different stages of neutrophil maturation in the bone marrow [90]. The 
first granules to be formed are the azurophilic (or primary) granules, followed by the 
specific (or secondary) granules. These granules contain numerous antimicrobial and 
potentially tissue-destructive components and they fuse primarily with phagocytic 
vacuoles. They are rather difficult to mobilize through fusion with the plasma mem-
brane. The gelatinase (or tertiary) granules, which are formed at a later time-point in 
the maturation process, are easily mobilized, and their content of receptors is moved 
to the cell surface. The most easily mobilized and receptor-rich secretory vesicles are 
the last to be formed, from the plasma membrane through an endocytic process [91, 
92]. Receptors that are mobilized to the cell surface from granules/vesicles include 
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the recently identified and partially characterized pattern recognition receptor FFA2R 
(a short-chain free fatty acid receptor, also called GPR43), which recognizes products 
derived from gut bacteria during the fermentation of dietary fibers, and the formyl 
peptide receptors (FPRs) that recognize formyl peptide, a hallmark of bacterial 
protein synthesis (described in more detail below) [111, 112]. 
Figure 6. The neutrophil NADPH-oxidase. The NADPH-oxidase comprises a membrane-localized b-type 
cytochrome (also referred to as the heterodimer of p22phox and gp91phox) and the cytosolic components 
p40phox, p47phox, and p67phox, as well as the cofactor Rac. Upon activation, cytosolic components trans-
locate to the b-type cytochrome-containing membranes to form a functional NADPH-oxidase, which is 
capable of producing reactive oxygen species (ROS). ROS production can occur either on the plasma mem-
brane, resulting in the release of extracellular ROS, or on the phagosomal (or granule) membrane during 
phagocytosis. The b-type cytochrome in the phagosome originates from the plasma membrane and from 
the fusion of specific granules. Another type of granule (azurophilic) that contains myeloperoxidase (MPO) 
is also recruited and participates together with the formed hydrogen peroxide to generate hypochlorous 
acid (HOCl-). 
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FORMYL PEPTIDE RECEPTORS 
In the mid-1970’s, Shiffmann et al. showed that synthetic peptides that contained an 
N–terminal formylated methionine (fMet) could act as chemoattractants for macro-
phages and neutrophils [113]. They postulated that peptides that contained N-fMet 
should be produced by prokaryotes and possibly constitute the chemotactic activity 
observed for the supernatant fluids obtained from bacterial cultures. Indeed, highly 
potent chemotactic fMet-containing peptides have since then been isolated from cul-
ture filtrates of a number of bacteria, including E. coli [114], S. aureus [115-118], M. 
avium [119], and L. monocytogenes [117, 120, 121]. It is important to note that not only 
bacteria, but also mitochondria initiate protein synthesis with an N-formylated me-
thionine, which means that damaged mitochondria also release danger signals in the 
form of formyl peptides that possess chemotactic activity for neutrophils [120, 122, 
123].  
The work of Shiffmann et al was soon followed by other studies that identified the 
formylated tripeptide fMLF (in the older literature, this is known as fMLP) as the 
most potent agonist of many different tested peptides. In 1990, the human receptor 
(originally FPR, now FPR1) for this peptide was cloned by screening a cDNA ex-
pression library that was constructed with mRNA species from differentiated HL-60 
cells [124-126]. Shortly thereafter, using low-stringency DNA hybridization screening 
(under conditions of reduced temperature and/or increased salt concentration), with 
the cDNA of human FPR1 as the probe, two additional FPR-like receptors were 
cloned and named FPRL1 (now FPR2) and FPRL2 (now FPR3), and the genes for 
all three are clustered together on chromosome 19 q13.3 in the human genome [127-
130]. Polymorphisms of the FPR1 gene have been described in patients who are suf-
fering from localized juvenile periodontitis, resulting in defects in Gi-protein coupling 
and reduced cell function [131, 132]. In addition, the FPR1 allele that contains an 
amino acid substitution in the C-terminal tail (abolishing its function) was associated 
with poor survival outcomes following chemotherapeutic treatment in patients who 
were suffering from breast and colorectal cancer [133, 134]. No polymorphisms in 
the coding regions of FPR2 or FPR3 have been described.  
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Although FPRs are mainly expressed by cells of myeloid origin, indicating a key role 
in innate immune reactions, they are also found in many other organs and tissues, 
including epithelial cells, liver hepatocytes, and Kuppfer cells, smooth muscle, and 
endothelial cells, as well as in neurons of the motor, sensory, and cerebellar systems 
[135]. The wide expression pattern of FPRs in non-immune cells suggests that they 
are also participating in other activities. Since this thesis deals mainly with neutrophils 
that express only FPR1 and FPR2, these two FPRs will be the focus hereafter.  
 
       
Figure 7. Sequence alignments of the human FPR1, FPR2, and FPR3 proteins. The UniProt alignments of 
FPR1 (UniProt ID: P21462), FPR2 (P25090) and FPR3 (P25089) are shown. Highlighted in pink are the trans-
membrane domains of the proteins. Under the sequences, the colons (:) indicate conservation. of residues 
between proteins with strongly similar properties, the asterisks (*) indicate fully conserved residues, and the 
periods (.) indicate conservation of residues between proteins with weakly similar properties. 
FPR signaling and regulation in neutrophils  
Human neutrophils express FPR1 and FPR2, whereas monocytes express all three 
members of the FPR family [136]. At the primary sequence level, FPR2 shares 69% 
identity with FPR1 and a higher level of homology (83%) with FPR3 (Figure 7) [127, 
130]. The two neutrophil FPRs share the highest levels of sequence similarities in 
their cytoplasmic signaling domains, which suggests that they transduce very similar 
signals through similar pathways and indeed, they trigger almost indistinguishable 
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cellular responses in neutrophils (Figure 7). The signaling pathways located down-
stream of FPR1 have been extensively studied, and details about the signal transduc-
tion pathways that participate in the induction of discrete neutrophil functions can 
be found in several recent reviews [137-139]. Agonist binding to FPRs leads primarily 
to signaling through the Gαiβγ-regulated signaling route, and once activated, the dis-
sociated Gαi-protein subunits activate multiple downstream second messengers, in-
cluding various phospholipases and protein kinases [140]. Based on the results 
obtained using a simple and straightforward system to measure β-arrestin binding, 
both FPR1 and FPR2 trigger translocation of β-arrestin, although the roles of this 
binding in signaling and functional responses have not been clearly defined. It is im-
portant to mention that unlike other GPCRs that rely on β-arrestin as the structural 
entity that is responsible for termination of G-protein signaling, desensitization of 
the FPRs relies in large part on binding to the actin cytoskeleton [141, 142]. That 
desensitized FPRs can be reactivated to produce superoxide by the addition of cyto-
skeleton-disrupting agents, such as cytochalasin B and latruculin A, strongly supports 
the idea that the cytoskeleton plays an important role. In addition, recent research 
has revealed that FPR reactivation can be induced by a novel receptor cross-talk 
mechanism, as illustrated by the reactivation of desensitized FPRs induced by ATP 
and PAF upon binding to their respective receptor [143]. This cross-talk signal gen-
erates a biased FPR response, as the reactivated receptor triggers assembly/activation 
of the NADPH-oxidase but no transient rise in the level of intracellular calcium [143].  
Conventional FPR agonists  
FPR1 was originally identified as a high-affinity receptor for formyl peptides. How-
ever, it has subsequently been discovered that one of the most prominent features of 
the FPRs is their ability to recognize many and diverse ligands, ranging from the 
formylated peptides, through non-formylated microbial/synthetic peptides and small 
molecules, to allosteric modulators, which include peptidomimetics and lipopeptides 
(see next section and Papers I–IV). Compared to FPR1, FPR2 displays a much more 
diverse ligand profile, and this receptor recognizes a broad range of molecules, in-
cluding the GP-41 envelope protein of the human immunodeficiency virus type 1 
(HIV-1), a peptide derived from glycoprotein G of herpes simplex virus type 2, Hp2-
20 from Helicobacter pylori, and the synthetic peptides WKYMVM/m. The reader is 
directed to other recent reviews for a full description of FPR -specific/-selective lig-
ands [140, 144-147]. FPR2 was for a long time regarded as an orphan, even though 
fMLF was known to be a low-affinity agonist. Soon after proper deorphanization, 
this receptor was shown to recognize a number of non-formylated agonists. How-
ever, formylated, phenol-soluble modulin (PSM) peptides, which are secreted by 
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methicillin-resistant Staphylococcus aureus (CA-MRSA), were recently identified as se-
lective and potent agonists of FPR2 [121]. In addition, several mitochondrion-de-
rived formyl peptides, such as mitocryptide, are preferentially recognized by FPR2 
but not by FPR1 [113, 120, 121, 148].  
 
When one compares the receptor preferences for formyl peptides of the two neutro-
phil FPRs, it appears that size is of importance, in that longer peptides prefer FPR2 
whereas shorter peptides (<10 amino acids) prefer FPR1, and the in-between peptide 
lengths are equally potent for FPR1 and FPR2 [120]. Moreover, host-derived mole-
cules have been suggested to act as FPR2 ligands, most notably the acute-phase pro-
tein SAA [166-168]. However, most (if not all) studies of the SAA-FPR2 complex 
have been performed with a recombinant protein that is a hybrid of two human SAA 
isoforms (SAA1 and SAA2) that do not exist in vivo [169]. It is debatable whether the 
idea of acute-phase SAA being a cytokine-like protein with pro-inflammatory prop-
erties really reflects the true biological activity of the endogenous SAA. Another host-
derived molecule that interacts with the FPRs belongs to the annexin family of cal-
cium-regulated, phospholipid-binding proteins that are involved in the regulation of 
Table 2. Overview of select FPR agonists, showing their origins and receptor specificities. 
Ligand(s) Origin Receptor preference Reference 
 
N-formylated 
    
fMLF E. coli FPR1 >> FPR2 [124, 149] 
fMIFL S. aureus FPR1 >> FPR2 [115, 150] 
fMIVIL L. monocytogenes FPR1 >> FPR2 [117, 120] 
PSMα2, PSMα3 CA-MRSA FPR2 >> FPR1 [121] 
Hp2-20 H. pylori FPR2 [151], 
 
Host-derived 
    
LL37 Cathelicidin FPR2 [152, 153] 
Annexin I Endogenous hu-
man protein 
FPR1, 2 [154-156] 
Aβ (1-42) Amyloid precur-
sor 
FPR2 [157] 
 
Peptide library 
    
WKYMVM Synthetic peptide FPR2 > FPR3 [158] 
WKYMVm Synthetic peptide FPR2 > FPR1 [158-160] 
MMK-1 Synthetic peptide FPR2 [161, 162] 
 
Small molecules 
    
Comp 43 High-throughput 
screening 
FPR1 > FPR2 [163, 164] 
 
Peptoidomimetic 
    
F2M2 Synthetic peptide FPR2 [165] 
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innate and adaptive immunity, although the receptor(s) involved in the different path-
ways have not been properly defined [148, 170-172]. 
As the FPRs have important regulatory functions in inflammation and in the patho-
genesis of various diseases, targeting FPRs with receptor-specific ligands (agonists, 
antagonists, and allosteric modulators) has great therapeutic potential for treating dis-
eases in which the inflammatory reaction is uncontrolled. Indeed, many FPR-
selective peptide/protein ligands, as well as stable and selective small-molecule lig-
ands have been identified over the last decades using high-throughput screening. It 
should be noted that it is of importance to determine the precise receptor specificity 
of “screening hits”, as illustrated by the case of the potent agonist compound 43, 
which although it was originally identified in a screening process with FPR2-
expressing cells, has been shown to interact preferentially with FPR1 [164]. The small 
molecules that are described as FPR agonists activate the preferred receptor also 
when expressed in naive human neutrophils, and the induced activities resemble 
those of pro-inflammatory peptides. 
Lipid inhibitors of innate immune cell function have recently been shown to be of 
physiological relevance for resolving inflammation, and it has been claimed that 
FPR2 is one of the receptors shared by mediators of the lipoxin and resolvin groups 
of lipid metabolites. When LXA4 (lipoxin A4) analogues from two commercial 
sources were used neither induced any translocation of β-arrestin, as measured in an 
enzyme fragment complementation assay [173]. Based on these results, it was con-
cluded that no signal is generated from FPR2 by LXA4 in neutrophils, and that the 
LXA4 effects on other cells are most likely mediated through an as yet unidentified 
receptor that is different from FPR2 [174]. In agreement with this conclusion, others 
have also failed to observe any FPR2-related effect of LXA4 [175]. 
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Conventional and allosteric FPR antagonists 
A recent search for new FPR antagonists, using a ligand-based virtual screening tech-
nique, identified 30 FPR antagonistic compounds, including the potent Quin-C7, be-
longing to different chemical families [176]. The same research group identified 
WKYMVM from a peptide library and subsequently, they discovered the FPR2 an-
tagonist WRWWWW (WRW4) [177]. With respect to FPR1 antagonists, the cyclic 
undecapeptide cyclosporine H (CysH) produced by fungi is the most potent and se-
lective. The mode of action is reduction of the basal activity of FPR1, which means 
that CysH is an inverse agonist [178, 179]. Replacing the formyl group of fMLF with 
a tertiary butyloxycarbonyl group (Boc-MLF, also known as Boc1) or replacement of 
the MLF sequence with FLFLF to yield Boc-FLFLF (also known as Boc2) generates 
FPR1 antagonists [149]. Boc1 and Boc2, when used at higher concentrations, partially 
inhibit FPR2 also [180].  
A rhodamine-conjugated, gelsolin-derived peptide (PBP10) has been identified as a 
potent inhibitor of FPR2. While it blocks FPR2-mediated responses without affect-
ing FPR1 signaling, the inhibitory effect is not entirely FPR2-specific, since some 
non-FPR2-mediated signaling is also inhibited [181-183]. The rhodamine group is 
required for the PBP10 peptide to pass through the plasma membrane and for the 
FPR2-specific inhibitory function of the peptide [181, 183, 184]. A core PBP peptide 
(RhoB-QRLFQVG) for FPR2 inhibition has been identified, and this shorter peptide 
partly inhibits also FPR1 [181], which suggests that a structure of importance for 
inhibition is present also in FPR1, although this is obviously not accessible for the 
longer peptide. It has been suggested that PBP10 modulates FPR2 from the cytosolic 
side, although it is difficult to prove conclusively that it interacts with its specific 
receptor from the inside of the plasma membrane. This is also the case for the FPR2 
pepducins (see below). The physicochemical properties (charge and hydrophobicity) 
that permit these membrane-permeable molecules to enter the cytoplasm are required 
for proper functionality, although that does not mean that they modulate receptor 
function from the cytosolic side of the membrane. The precise site of action of PBP10 
remains unresolved. It is worth noting, however, that PBP10 inhibits the cellular re-
sponse induced by allosteric FPR2-activating pepducins (see below). 
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Table 3. List of select FPR antagonists, showing their origins and receptor specificities. 
Ligands  Source  Receptor  Literature  
    
Conventional ligands 
    
CysH T. inflatum FPR1 [185] 
CHIPS S. aureus FPR1 [186]  
FLIPr S. aureus  FPR2 >> FPR1 [187] 
PBP10 Binding domain of gelsolin FPR2 >> FPR3 [181] 
    
Peptide library 
    
WRW4 Synthetic peptide  FPR2 >> FPR3 [177] 
Boc1 Synthetic peptide  FPR1 >> FPR2 [149] 
Boc2 Synthetic peptide  FPR1 >> FPR2 [149] 
    
Peptidomimetic 
    
Cmp. 1 Synthetic peptidomimetic FPR2 [188] 
    
 
FPR2-derived pepducins activate FPR2  
Given that they have the capacity to permeate cell membranes and allosterically mod-
ulate GPCR function, pepducins should also be able to interact with neutrophil 
GPCRs, thereby providing unique tools for the regulation of innate immune-related 
activities. Accordingly, neutrophil-activating pepducins were recently described as 
having in common, peptides with amino acid sequences identical to the whole or 
parts of the third intracellular loop of FPR2 linked to a fatty acid [75]. Interestingly, 
the most potent peptide is not the one that contains the entire loop (16 amino acids) 
but the F2Pal10 peptide, which contains 10 amino acids (Paper I). These FPR2-
activating pepducins are highly FPR2-selective, as it has been shown that they are 
inactive in FPR1-transfected cells and that their activities in neutrophils are insensi-
tive to the FPR1-specific antagonist CysH [75]. The pepducin concept proposes that 
receptor selectivity is manifested through the sequence identity between the pepducin 
and the intracellular loop of the targeted receptor, although it is difficult to under-
stand how these two sequences act together to modulate receptor intracellular signal-
ing. Studies using a chimeric FPR1-FPR2 receptor in which the third intracellular 
loop of FPR2 (from which the FPR2-activating pepducin is derived) was replaced 
with that of the FPR1 (pepducin-insensitive) showed that the chimeric receptor still 
recognizes the pepducin, suggesting that there is no direct linkage between the amino 
acid sequence in the activating pepducin and that in the third intracellular loop of the 
activated receptor [75]. F2Pal10 triggers a neutrophil activation pattern that is very 
similar to that induced by conventional FPR2 agonists, despite the fact that pepducins 
and conventional agonists initiate signaling through different mechanisms, with “in-
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side-in” signaling seen for pepducins and “outside-in” signaling observed for extra-
cellular agonists. It is known that FPR2 cross-talks with other GPCRs, such as PAFR 
and P2Y2R, through a unique but not yet understood signaling pathway that leads to 
FPR2 reactivation [143]. Both conventional and allosteric FPR2 modulators can in-
duce this cross-talk, although the F2Pal10 pepducin is more strongly biased toward 
this signaling than the conventional FPR2 agonist [189]. Thus, there may be some 
signaling differences between conventional and allosteric agonists. 
The process termed "insertion and inversion", which entails the pepducin incorpo-
rating its lipid tail into the phospholipid bilayer, thereby enabling the peptide part of 
the construct to flip over the membrane and become exposed on the cytosolic side 
of the membrane, is suggested as the basic mechanism through which pepducins 
mediate their activities (Figure 5). As a consequence of this process, the lipid part is 
a prerequisite for activity, and this is also true for the FPR2 pepducins, as no activity 
was obtained with non-lipidated peptides [54]. It is also clear that the FPR2 pepducins 
are highly selective for the receptor, possessing sequence identity with the pepducin 
peptide, which is in agreement with the concept. However, some of the reported 
results raise questions regarding the precise mechanism of action. For example, the 
FPR2 pepducin inhibits the binding of a conventional peptide agonist that is selective 
for FPR2, and this inhibition occurs also at temperatures (e.g., 4°C) at which it must 
be very difficult for the pepducins to pass through the plasma membrane (Paper II). 
We should perhaps not assume that all pepducins act on the intracellular region of 
the specifically targeted GPCR and induce their effects through so-called allosteric 
modulation of intracellular receptor domains that couple to G-proteins and other 
signaling/regulating proteins. Instead, we should consider the possibility that there 
are different, and possibly unique, modes of action related to each individual 
pepducin/receptor pair. 
Bacterial killing and immunomodulation 
It is well established that the allosteric modulatory activity of pepducins relies on both 
the lipid anchor and the peptide sequence, and this is also true for the bacterial killing 
activities of known antimicrobial lipopeptides. Thus, immunomodulatory pepducins, 
being lipopeptides, may also have direct killing effects on bacteria [153, 190]. Accord-
ingly, the direct antimicrobial activities of FPR2 pepducins were assayed, and the 
structural/physicochemical features of pepducins that link receptor activation and 
bacterial killing were exploited. The physicochemical properties of the lipopeptides 
are of importance both for their abilities to activate neutrophils and for killing bacte-
ria, although there are no direct linkages between the two functions (Paper I). Alt-
hough FPR2 pepducins have off-target effects that are independent of FPR2, this 
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functional dualism of pepducins could be explored as a novel class of antibacterial 
drugs with immunomodulatory properties. These results raise the possibility that 
other antimicrobial lipopeptides have immunomodulatory effects– an idea that war-
rants investigation.  
Peptidomimetics, which are partly composed of unnatural residues, are proteolytically 
stable against endogenous protease degradation and may be designed to mimic im-
munomodulatory host defense peptides [188], as well as to share structural similarities 
with lipopeptides, such as the pepducins. Accordingly, the recently discovered FPR2-
selective modulators belong to the class of lipidated α-peptide/β-peptoid hybrids. By 
screening a small array of a peptidomimetic library, using GPCR-dependent neutro-
phil production of superoxide as a read-out, both activating and inhibiting pep-
tidomimetics that target specifically FPR2 were recently identified [165, 188]. The 
most promising compound, Pam-(Lys-βNSpe)6-NH2, was shown to inhibit FPR2 ag-
onist-induced neutrophil granule mobilization and the release of ROS. The potency 
of Pam-(Lys-βNSpe)6-NH2 was comparable to that of PBP10, which is the most po-
tent FPR2-selective inhibitor known, and combining these two agents gave an addi-
tive effect [188]. The rhodamine group in the core PBP10 peptide cannot be 
exchanged for palmitic acid [181], suggesting that the mechanisms of action might 
differ between the lipopeptoid and PBP10. This notion is supported by the finding 
that PBP10 has no effect on the mouse receptor, whereas the lipopeptoid inhibits the 
function of this receptor (see below and Paper III). The immunomodulatory effects 
of structural analogs of Pam-(Lys-βNSpe)6-NH2 emphasize the importance of both 
the lipid and peptidomimetic parts [188]. In addition, we have identified Lau-((S)-
Aoc)-(Lys-βNphe)6-NH2 as a potent FPR2 activator [165]. Further analyses of a num-
ber of structural variants have revealed that the N-acyl 2-aminooctanoic acid residue 
and the peptidomimetic backbone of the molecule are both required for the agonistic 
activity. This novel class of FPR2-modulating peptidomimetic ligands may serve as 
valuable tools for further delineation of the ligand recognition and signaling mediated 
by FPR2, as well as for exploring the therapeutic potential of targeting FPR2 in dis-
ease.  
Receptor hijacking: FPR2-interacting pepducins with amino 
acid sequences derived from other GPCRs 
Pepducins can activate receptors, as shown for the FPR2 third intracellular loop 
pepducins that are highly specific for this receptor, and despite their extensive se-
quence similarity with FPR1 (69% amino acid identity), there is no cross-activation 
of this receptor. Pepducins can, however, have the opposite effect and inhibit the 
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function of the targeted receptor, and this is true for the pepducin derived from the 
third intracellular loop of FPR1-inhibited neutrophils, although the target in this case 
is not FPR1. The 16-amino acid pepducin derived from the third intracellular loop 
of FPR1 potently inhibited neutrophil functions, and unexpectedly, the identity of 
the targeted receptor was found to be FPR2. Thus, FPR1 pepducin hijacks the closely 
related FPR2 (Paper II). This type of cross-reactivity has been described earlier for 
other closely related receptors, such as the PAR and the β-adrenergic receptors [191]. 
The concept of inherent receptor selectivity for a given pepducin is obviously not 
always valid. In agreement with results obtained with FPR2-activating pepducins, 
FPR1 also competes for binding with FPR2-specific agonists (Paper II), once again 
suggesting that there is no single mechanism through which pepducins selectively 
activate/inhibit GPCRs. One possible explanation for the results obtained from the 
competitive binding experiments is that FPR2-specific pepducins, irrespective of 
origin, are also recognized by the cell surface-exposed agonist-binding domain of 
FPR2. Regardless of the precise mechanism of action, it is clear the neither of the 
two pepducin parts work on their own. As there is only a very small difference (ac-
tually, one amino acid) between the activating and inhibiting pepducins, it is reason-
able to hypothesize that this is the basis for the hijacking phenomenon. Results 
obtained with pepducins that have peptide sequences identical to the intracellular 
loops of CXCR4 (the CXCL12 receptor) and P2Y2R (the ATP receptor) are discrep-
ant with this hypothesis. The receptor-desensitization profiles and the inhibitory ef-
fects of receptor-selective agonists/inhibitors indicate that these pepducins also 
hijack FPR2 [78, 189]. It is also worth noting that the P2Y2R pepducin converts its 
natural agonist to an activator of the neutrophil NADPH-oxidase. The third intracel-
lular loop pepducin both activates and desensitizes FPR2, and when it comes to direct 
activation, the pepducin is a partial agonist [143]. However, the reactivation of deac-
tivated receptors is much more pronounced, and in this system, the pepducin should 
be classified as a full agonist. These results raise general questions not only about the 
precise mechanism by which pepducins specifically activate GPCRs, but also about 
ligand recognition of lipopeptides by FPR2. It is clear from earlier studies on the 
structure-function relationships of pepducins, as well as other peptides, that their 
activities as FPR agonists are not dictated solely by the amino acids that access the 
presumed ligand-binding pockets of the receptors [75, 150] (Paper II). The physico-
chemical properties of the regions of agonistic peptides that do not have direct access 
to the binding site are just as important for the interaction with FPR2, as are the 
amino acids that putatively fit into the binding pocket [150, 181]. This suggests that 
endogenous or microbe-derived, lipid-substituted peptides represent an additional 
molecular pattern that is recognized by FPR2. However, it is important to point out 
that there are stringent structural requirements for recognition. This is illustrated by 
the facts that a number of pepducins are not recognized by FPR2 and that the amino 
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acid sequence is of importance for recognition, as are the positions of the charged 
amino acids in the peptide chain, rather than the net charge, as well as the length of 
the peptide (Paper I) [189]. 
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MODULATION OF FPR FUNCTIONS 
 IN MICE NEUTROPHILS 
The innate immune system differs substantially between mouse and man. In the 
mouse, neutrophils constitute only around 10%–25% of the circulating leukocytes, 
whereas 50%–70% of the leukocytes in humans are neutrophils [192, 193]. Another 
prominent difference between these species is the appearance of the family of FPRs, 
which has undergone extensive expansion across species [145]. The receptors differ 
substantially in terms of their ligand recognition profiles, making it very challenging 
to translate experimental data obtained in mouse models to the human setting. How-
ever, to understand the basic biochemical mechanisms underlying cell function and 
to develop new strategies for therapeutic intervention and preclinical testing, mouse 
models of human disease are necessary.  
Fprs in mice neutrophils 
Functional FPR1 orthologs have been identified in several animal species, such as 
primates, rabbits, horses, rats, guinea pigs, and mice [194-199]. With respect to the 
mouse, there are at least eight Fpr family members (Fpr1 and Fpr-rs 1–7) encoded in 
the mouse genome, clustered on chromosome 17 in a region of conserved synteny 
with human chromosome 19, where the three FPR genes are located [200, 201]. All 
of the mice Fprs, with the exceptions of Fpr-rs5, which most probably is a pseudo-
gene, are expressed as functional receptors [200]. Fpr1, Fpr2, and Fpr-rs1 are ex-
pressed by mice leukocytes, and Fpr1 is the FPR1 mice ortholog with 72% sequence 
identity, whereas Fpr2 is suggested to be the FPR2 ortholog with 76% sequence iden-
tity [145]. The remaining Fpr members are expressed mainly by the vomeronasal or-
gan (an olfactory structure in the nasal septum that detects pheromones and other 
social cues) and skeletal muscle cells [202, 203].   
Studies using animals that are genetically knocked out for Fpr1 or/and Fpr2 reveal 
that these receptor-deficient animals are viable, fertile, and display normal anatomy 
and physiology. Both Fpr1-/- and Fpr2-/- mice have dysregulated immune responses 
MODULATION OF FPR FUNCTIONS 
 IN MICE NEUTROPHILS 
34 
under stress conditions, such as bacterial infections and sterile inflammation [123, 
204-208]. Animals that were treated with the Fpr agonist WKYMVm were shown to 
be protected against disease in a severe sepsis mouse model [209], suggesting that the 
receptor(s) are important modulators of inflammation. 
Ligand recognition differences between the  
receptors in mouse and man  
Earlier work clearly demonstrated that FPRs and their mice counterparts differ sub-
stantially with respect to their ligand-binding profiles, as illustrated by the fact that 
the most potent and selective FPR1 and FPR2 antagonists, i.e., CysH and PBP10, 
respectively, have no effects on the mouse receptors (Paper III). Moreover, the pro-
totype and potent FPR1 agonist fMLF is a very poor agonist for the Fprs. Similarly, 
the potent FPR2 agonists WKYMVM and MMK-1 have low (WKYMVM) and no 
(MMK-1) activities in terms of activating mice neutrophils (Paper III and Table 5). 
Formyl peptides derived from L. monocytogenes (with the sequence fMIVIL) and S. 
aureus (with the sequence fMIFL) have been found to be much more potent than 
fMLF in stimulating mice neutrophils [117], and this phenomenon has been con-
firmed with both wild-type and Fpr2−/− cells (Paper III). Fpr1 has been identified as 
Table 4. Sequence identity (percentage) between the human and mice FPRs1. 
Size2 Name FPR1 FPR2 FPR3 
Fpr
1 
Fpr-
rs1 
Fpr
2 
Fpr-
rs3 
Fpr-
rs4 
Fpr-
rs6 
Frp-
rs7 
350 FPR1 100 69 58 72 60 64 56 52 51 50 
351 FPR2  100 72 64 74 76 65 62 59 58 
353 FPR3   100 52 61 63 54 52 50 51 
364 Fpr1    100 56 60 53 50 50 50 
347 Fpr-rs1     100 81 66 62 58 60 
351 Fpr2      100 66 64 59 60 
343 Fpr-rs3       100 78 74 73 
323 Fpr-rs4        100 70 70 
339 Fpr-rs6         100 94 
338 Fpr-rs7          100 
1Data listed were obtained from UniProt: FPR1 (UniProt ID: P21462); FPR2 (P25090); FPR3 (P25089); Fpr1 
(P33766); Fpr-rs1 (O08790); Fpr2 (O88536);  Fpr-rs3 (O88537); Fpr-rs4 (A4FUQ5); Fpr-rs6 (Q3SXG2); and 
Fpr-rs7 (Q71MR7) 
2Number of amino acids 
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the preferred receptor for a number of fMet-containing peptides that are also recog-
nized by the H2-M3 complex, which presents N-formylated peptides to cytotoxic T 
cells [210]. In this study, we show no direct correlation between the activities induced 
by the different peptides in human and mice neutrophils, respectively, although we 
found that some of the peptides were more potent activators of Fpr1 than of the 
human receptor. Moreover, the structural requirements differed between the H2-M3 
and FPR/Fpr, which suggests that these two recognition systems have followed dif-
ferent evolutionary paths.  
The S. aureus-derived, phenol-soluble modulin PSMα2, which was earlier shown to 
be a potent FPR2 agonist, proved to be a potent activator of neutrophils that origi-
nated from normal wild-type animals, whereas no activity was induced in Fpr2−/− 
cells, clearly identifying this peptide as an Fpr2-selective agonist (Paper III). Some 
dual FPR1/FPR2 agonists act as dual agonists also in the mouse, being recognized 
by both Fpr1 and Fpr2 [174, 211].  
Until very recently, there were very few molecular tools available in the form of well-
characterized Fpr-specific antagonists. The earlier-mentioned Boc1 and Boc2 pep-
tides have been suggested to inhibit primarily Fpr2, although Boc1 has no inhibitory 
effect and Boc2 is primarily an Fpr1 antagonist. The FPR2-selective peptide inhibitor 
WRW4 is active also against Fpr2, albeit with a potency that is lower than that of the 
newly identified and described peptidomimetic inhibitor (Paper III). Taken together, 
the observed similarities and difference between FPRs and Fprs in terms of ligand 
recognition profiles highlight how important it will be in future research studies to 
choose appropriate ligands when designing animal experiments.   
Table 5. Effects of selected human FPR agonists on human and mice neutrophils1. 
Agonist Activity in human 
neutrophils2 
Activity in mouse 
neutrophils2 
 FPR1 FPR2 Fpr1 Fpr2 
fMIFL +++ - +++ - 
fMLF +++ - + - 
fMIFL-PSMα25-16 +++ +++ ++ +++ 
Comp43 ++ + ++ + 
WKYMVm ++ +++ +++ +++ 
WKYMVM - +++ - + 
PSMα2 - +++ - +++ 
PSM α21-16 - ++ - ++ 
MMK-1 - ++ - - 
1 The figure is adapted from Paper III. 
2 +++ = very potent; ++ = potent; + = weak; – = inactive. 
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Table 6. Effects of selected human FPR antagonists on human and mice neutrophils. 
Antagonist Activity in human 
neutrophils2 
Activity in mouse 
neutrophils2 
 FPR1 FPR2 Fpr1 Fpr2 
CysH +++ - - - 
PBP10 - +++ - - 
WRW4 - ++ - ++ 
Boc1 + - + - 
Boc2 ++ - ++ - 
Lau-(Lys-βNSpe)6-NH2 - ++ - ++ 
Pam-(Lys-βNSpe)6-NH2 - +++ ++ +++ 
Ac-(Lys-βNSpe)6-NH2 - - - - 
1 The listed activities are taken from the results presented in Paper III.  
2 +++ = very potent; ++ = potent; + = weak; – = inactive. 
Allosteric modulators of Fpr function  
In similarity to FPR2, Fpr2 recognizes both pepducins and proteolytically stable pep-
tidomimetics, as illustrated by the finding that the recently described α-peptide/β-
peptoid (F2M2) stimulates superoxide production when it interacts with both mice 
and human neutrophils, and the targeted receptors are FPR2/Fpr2 [165]. When ex-
amining the FPR2-activating pepducins in relation to mice neutrophils, it became 
clear that mice neutrophils are also activated, and that basically this is achieved 
through the targeting of Fpr2 (Paper IV). It is worth mentioning that in contrast to 
its inhibitory effect on FPR2, the FPR1 pepducin (F1Pal16) positively modulates Fpr2 
and activates mice neutrophils. Future studies should aim at elucidating the modula-
tion mechanism that underlies the activation effect of F1Pal16 on Fpr2 and the inhib-
itory effect of F1Pal16 on FPR2. Pepducins that have inhibitory effects on Fpr2 have 
also been identified, with the most potent one having a peptide sequence that is iden-
tical to the third intracellular loop of Fpr2. In similarity to the FPR1-derived pepducin 
F1Pal16, the corresponding Fpr1-derived pepducin is an agonist for mice neutrophils 
but acts as an inhibitor for human neutrophils, and the effect is mediated through 
the hijacking of Fpr2 and FPR2, respectively, without affecting the closely related 
FPR1/Fpr1 (Paper IV). The identification of these Fpr-activating and -inhibiting 
pepducins provides not only valuable tools to study in greater detail FPR/Fpr allo-
steric modulation, but it also raises questions regarding the pepducin concept with 
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respect to the mechanism used to achieve receptor specificity. In addition, the pre-
sented data suggest that there may be an as yet unidentified molecular pattern for 
FPR2/Fpr2 recognition.  
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GPCRs are the largest and most important group of cell-surface receptors that par-
ticipate in the regulation of almost all aspects of cellular functioning. Recent research 
on GPCRs has led to a number of novel concepts with respect to receptor regulation, 
including biased signaling, allosteric modulation (both positive and negative), differ-
ent levels of receptor cross-talk, as well as functional selectivity. The pepducin prin-
ciple is an illustrative example of the selective allosteric modulation concept, in which 
a unique type of molecule acts from the cytosolic side of the receptor-expressing 
membrane and affects the signaling part of the targeted GPCR. Many GPCR-
modulating pepducins have been successfully generated, and it is clear that allosteric 
modulators have potential advantages over orthosteric agonists/antagonist as thera-
peutic agents. In line with this, some pepducins have already entered into clinical 
trials. Nonetheless, the precise mechanism of action of pepducins is currently unclear, 
and this is particularly evident when it comes to the FPR-interacting pepducins, as 
illustrated by the fact that some of the results presented in this thesis are discrepant 
with the current concept of how pepducins regulate GPCRs. Future studies should 
aim to elucidate the general mechanisms (if any) of action (positive as well as nega-
tive) of the pepducin group of allosteric modulators.  
There is strong evidence that FPRs are involved in several aspects of tissue homeo-
stasis, host defense reactivity, and regulation of immune reactions and inflammation, 
which serves to highlight these receptors as promising targets for the future design 
of anti-infective and anti-inflammatory agents. However, more knowledge is needed 
regarding the basic pharmacological characterization and fine-tuning of FPR activi-
ties before it will be possible to define the full therapeutic potential. In this thesis, the 
identification of cross-species ligand recognition provides useful tools to investigate 
the physiological function of FPR2, as well as the therapeutic potential of targeting 
Fpr2 in a mouse model of human disease. While the molecular pattern recognized by 
FPR1 is well-established, no such pattern has yet been defined for FPR2. The studies 
presented in this thesis reveal that both lipopeptides and lipopeptidomimetics specif-
ically bind to FPR2, suggesting a common feature that could be the basis for recog-
nition by FPR2. Nevertheless, future research should aim to understand the basis of 
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FPR2/Fpr2 as a pattern recognition receptor, as well as to identify such FPR2-
binding peptides in vivo. 
Finally, knowledge obtained from the studies using FPRs as a model GPCR should 
facilitate our understanding of receptor modulation in general, and more importantly, 
will be of importance in terms of our abilities to develop FPR2-based immunomod-
ulatory therapeutics in the future. 
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